ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

How to Reduce Gout Flares

Keri Losavio  |  November 12, 2023

SAN DIEGO—If patients with gout keep their serum urate (SU) levels very low with urate-lowering therapy (ULT), they have fewer flares, according to a research abstract presented at ACR Convergence 2023.

Filed under:ACR ConvergenceConditionsGout and Crystalline ArthritisMeeting ReportsResearch Rheum Tagged with:ACR Convergence 2023Gout Resource Center

Welcome to ACR Convergence!

Keri Losavio  |  November 11, 2023

SAN DIEGO—Award presentations & artificial intelligence topped the list in the ACR Convergence 2023 Opening Session & Keynote Lecture on Nov. 11.

Filed under:ACR ConvergenceAwardsMeeting ReportsProfessional Topics Tagged with:ACR Convergence 2023artificial intelligence

Pakistani-Native Dr. Iman Qaiser Serves Choctaw Nation in Oklahoma

Elizabeth Hofheinz, MPH, MEd  |  November 10, 2023

Some people may think Pakistan and Oklahoma share little in common, but one recent graduate of the rheumatology fellowship program at Louisiana State University, Shreveport (LSUS), School of Medicine disagrees. Iman Qaiser, MD, MBBS, a native of Pakistan who is starting a role as the only rheumatologist serving the Choctaw Nation of Oklahoma, sees natural…

Filed under:ProfilesWorkforce Tagged with:Dr. Iman Qaiser

Case Report: Pneumatosis Cystoides Intestinalis

Jagmohan S. Jandu, MD, MA, Sri Harsha Boppana, MD, Prahlad A. Reddy, MD, & Atigadda N. Reddy, MD, FACP, FACG, AGAF  |  November 8, 2023

Pneumatosis cystoides intestinalis (PCI) is a rare gastrointestinal pathological process defined by the presence of gas within the layers of the intestinal wall, commonly within the mucosa and submucosa of the small and large intestines.2,3 PCI has been described in the literature in association with various connective tissue diseases, including scleroderma, mixed connective tissue disease,…

Filed under:ConditionsSystemic Sclerosis Tagged with:case reportpneumatosis cystoides intestinalis (PCI)

Beyond the Clinic: Lessons Learned from a Rheumatologist with RA

Linda Childers  |  November 7, 2023

A pediatric rheumatologist diagnosed with RA following the birth of her first child talks about integrative care & offers tips for helping patients reduce the symptom burden. 

Filed under:Patient PerspectiveRheumatoid Arthritis Tagged with:RA Resource CenterRheumatoid Arthritis (RA)

FDA Approves New Biosimilar for Adult & Pediatric Arthritis

Michele B. Kaufman, PharmD, BCGP  |  November 6, 2023

This year, tocilizumab biosimilars have been approved to treat adult and pediatric patients with rheumatic disease, including rheumatoid arthritis, juvenile idiopathic arthritis and more, in both Europe and the U.S.

Filed under:Biologics/DMARDsDrug UpdatesPediatric ConditionsRheumatoid Arthritis Tagged with:BiosimilarstocilizumabU.S. Food and Drug Administration (FDA)

FDA Approves Canakinumab to Treat Gout Flares

Michele B. Kaufman, PharmD, BCGP  |  November 3, 2023

Canakinumab has received FDA approval for the treatment of patients with acute gout flares.

Filed under:Biologics/DMARDsDrug UpdatesGout and Crystalline Arthritis Tagged with:canakinumabFDA approvalGout Resource CenterU.S. Food and Drug Administration (FDA)

FDA Accepts NDA for Investigational RA Agent

Michele B. Kaufman, PharmD, BCGP  |  November 1, 2023

The FDA has accepted an investigational new drug application (NDA) for MYMD-1, an oral tumor necrosis factor-α inhibitor for patients with rheumatoid arthritis.

Filed under:Biologics/DMARDsDrug UpdatesRheumatoid Arthritis Tagged with:tumor necrosis factor (TNF) inhibitorsU.S. Food and Drug Administration (FDA)

When Is Arthroplasty Recommended? New ACR/AAHKS Guideline Offers Considerations for Timing of Elective Hip or Knee Arthroplasty

Ruth Jessen Hickman, MD  |  November 1, 2023

The ACR released a new arthroplasty guideline in an effort to remedy significant & detrimental delays faced by osteoarthritis or osteonecrosis patients who require surgical intervention.

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceOsteoarthritis and Bone Disorders Tagged with:arthroplastyrecommendations

Are We Making Progress in Treating Lupus? Clinical Insights from Dr. Michelle Petri

Jason Liebowitz, MD, FACR  |  November 1, 2023

At the 19th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases course, Dr. Michelle Petri gave a presentation concerning the overall state of lupus treatment outcomes in the U.S.

Filed under:ConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:glucocorticoidHydroxychloroquine (HCQ)

  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • …
  • 327
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences